ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
September 16, 2013 7:00 AM UTC
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.07 to $114.14 on Friday after Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS).
Earlier in the week, Alexion said NHS England will cover Soliris to treat aHUS pending a decision from NICE, which is expected in spring 2014. Soliris is approved in the EU and U.S. for aHUS, and in more than 40 countries, including the EU, to treat paroxysmal nocturnal hemoglobinuria (PNH). Alexion was up $2.58 on the week...